Full Text:   <1082>

Summary:  <482>

CLC number: R730.51

On-line Access: 2015-09-05

Received: 2014-12-31

Revision Accepted: 2015-05-05

Crosschecked: 2015-08-10

Cited: 4

Clicked: 2102

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Xiao-peng Lan

http://orcid.org/0000-0003-1482-8952

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2015 Vol.16 No.9 P.743-756

10.1631/jzus.B1500003


Immunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients


Author(s):  Xiao-peng Lan, You-gen Chen, Zheng Wang, Chuan-wei Yuan, Gang-gang Wang, Guo-liang Lu, Shao-wei Mao, Xun-bo Jin, Qing-hua Xia

Affiliation(s):  Minimally Invasive Urology Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250014, China

Corresponding email(s):   xqhgege@hotmail.com

Key Words:  Solid carcinoma, Meta-analysis, Dendritic cells, Cytokine-induced killer cells, Immunotherapy


Xiao-peng Lan, You-gen Chen, Zheng Wang, Chuan-wei Yuan, Gang-gang Wang, Guo-liang Lu, Shao-wei Mao, Xun-bo Jin, Qing-hua Xia. Immunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients[J]. Journal of Zhejiang University Science B, 2015, 16(9): 743-756.

@article{title="Immunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients",
author="Xiao-peng Lan, You-gen Chen, Zheng Wang, Chuan-wei Yuan, Gang-gang Wang, Guo-liang Lu, Shao-wei Mao, Xun-bo Jin, Qing-hua Xia",
journal="Journal of Zhejiang University Science B",
volume="16",
number="9",
pages="743-756",
year="2015",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1500003"
}

%0 Journal Article
%T Immunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients
%A Xiao-peng Lan
%A You-gen Chen
%A Zheng Wang
%A Chuan-wei Yuan
%A Gang-gang Wang
%A Guo-liang Lu
%A Shao-wei Mao
%A Xun-bo Jin
%A Qing-hua Xia
%J Journal of Zhejiang University SCIENCE B
%V 16
%N 9
%P 743-756
%@ 1673-1581
%D 2015
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1500003

TY - JOUR
T1 - Immunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients
A1 - Xiao-peng Lan
A1 - You-gen Chen
A1 - Zheng Wang
A1 - Chuan-wei Yuan
A1 - Gang-gang Wang
A1 - Guo-liang Lu
A1 - Shao-wei Mao
A1 - Xun-bo Jin
A1 - Qing-hua Xia
J0 - Journal of Zhejiang University Science B
VL - 16
IS - 9
SP - 743
EP - 756
%@ 1673-1581
Y1 - 2015
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1500003


Abstract: 
Objective: Professional antigen-presenting dendritic cells (DCs) and cytokine-induced killer (CIK) cells, components of anti-cancer therapy, have shown clinical benefits and potential to overcome chemotherapeutic resistance. To evaluate whether DC-CIK cell-based therapy improves the clinical efficacy of chemotherapy, we reviewed the literature on DC-CIK cells and meta-analyzed randomized controlled trials (RCTs). Methods: We searched several databases and selected studies using predefined criteria. RCTs that applied chemotherapy with and without DC-CIK cells separately in two groups were included. Odds ratio (OR) and mean difference (MD) were reported to measure the pooled effect. Results: Twelve reported RCTs (826 patients), which were all performed on Chinese patients, were included. Combination therapy exhibited better data than chemotherapy: 1-year overall survival (OS) (OR=0.22, P<0.01), 2-year OS (OR=0.28, P<0.01), 3-year OS (OR=0.41, P<0.01), 1-year disease-free survival (DFS) (OR=0.16, P<0.05), 3-year DFS (OR=0.32, P<0.01), objective response rate (ORR) (OR=0.54, P<0.01), and disease control rate (DCR) (OR=0.46, P<0.01). Moreover, the levels of CD3+ T-lymphocytes (MD=−11.65, P<0.05) and CD4+ T-lymphocytes (MD=−8.18, P<0.01) of the combination group were higher. Conclusions: immunotherapy of DC-CIK cells may enhance the efficacy of chemotherapy on solid cancer and induces no specific side effect. Further RCTs with no publishing bias should be designed to confirm the immunotherapeutic effects of DC-CIK cells.

DC-CIK细胞免疫治疗联合化疗对实体肿瘤疗效的荟萃分析

目的:分析和研究DC-CIK细胞免疫治疗是否能够增强化疗在实体肿瘤中的疗效。
创新点:首次荟萃分析了关于DC-CIK细胞免疫治疗联合化疗治疗肿瘤疗效的随机对照试验,并从多个角度对疗效进行综合评价。
方法:通过文献检索及筛选,收集关于化疗联合DC-CIK细胞免疫治疗的随机对照试验(图1),并从中提取相关数据进行荟萃分析。总生存率(OS)、无病生存率(DFS)、客观缓解率(ORR)、疾病控制率(DFS)和治疗后T淋巴细胞亚型水平是本研究中的主要疗效指标,比值比(OR)(图3、4和5)以及平均差(MD)(图6)用来评价各个指标的综合效应。
结论:共有12个随机对照试验被纳入我们的研究中(表1和2)。相对于单独应用化疗,DC-CIK细胞治疗联合化疗的综合疗法能在1年生存率、2年生存率、3年生存率、1年无病生存率、3年无病生存率、客观缓解率以及疾病控制率等指标上有明显优势,且接受综合疗法患者的CD3+ T淋巴细胞和CD4+ T淋巴细胞水平明显更高。综上所述,DC-CIK细胞免疫治疗能够增强化疗对实体肿瘤的疗效。

关键词:实体肿瘤;荟萃分析;树突状细胞;细胞因子诱导杀伤细胞;免疫治疗

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Anguille, S., Smits, E.L., Lion, E., et al., 2014. Clinical use of dendritic cells for cancer therapy. Lancet Oncol., 15(7):e257-e267.

[2]Baek, S., Lee, S.J., Kim, M.J., et al., 2012. Dendritic cell (DC) vaccine in mouse lung cancer minimal residual model; comparison of monocyte-derived DC vs. hematopoietic stem cell derived-DC. Immune Netw., 12(6):269-276.

[3]Conniot, J., Silva, J.M., Fernandes, J.G., et al., 2014. Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Front. Chem., 2:105.

[4]Dunn, G.P., Old, L.J., Schreiber, R.D., 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 21(2):137-148.

[5]Gabrilovich, D.I., Ostrand-Rosenberg, S., Bronte, V., 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol., 12(4):253-268.

[6]Gao, D., Li, C., Xie, X., et al., 2014. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS ONE, 9(4):e93886.

[7]Hanahan, D., Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. Cell, 144(5):646-674.

[8]Hao, M.Z., Lin, H.L., Chen, Q., et al., 2010. Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study. Chin. J. Cancer, 29(2):172-177.

[9]Introna, M., Borleri, G., Conti, E., et al., 2007. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica, 92(7):952-959.

[10]Introna, M., Pievani, A., Borleri, G., et al., 2010. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol. Blood Marrow Transplant., 16(11):1603-1607.

[11]Jiang, J., Wu, C., Lu, B., 2013. Cytokine-induced killer cells promote antitumor immunity. J. Transl. Med., 11(1):83.

[12]Li, H., Wang, C., Yu, J., et al., 2009. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy, 11(8):1076-1083.

[13]Li, S., Li, Y., Liang, J., et al., 2012. The study of clinical application of DC-CIK combined with chemotherapy on colon cancer. Chin. J. Immunol., 9:835-839 (in Chinese).

[14]Linn, Y.C., Lau, L.C., Hui, K.M., 2002. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br. J. Haematol., 116(1):78-86.

[15]Linn, Y.C., Niam, M., Chu, S., et al., 2012a. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant., 47(7):957-966.

[16]Linn, Y.C., Yong, H.X., Niam, M., et al., 2012b. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy, 14(7):851-859.

[17]Liu, L., Zhang, W., Qi, X., et al., 2012. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin. Cancer Res., 18(6):1751-1759.

[18]Liu, P., Chen, L., Huang, X., 2009. The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Cancer Biother. Radiopharm., 24(1):91-98.

[19]Liu, Q., Wang, Y., Wang, H., et al., 2013. Tandem therapy for retinoblastoma: immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis. J. Cancer Res. Clin. Oncol., 139(8):1357-1372.

[20]Ma, Y., Zhang, Z., Tang, L., et al., 2012. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy, 14(4):483-493.

[21]McGray, A.J., Hallett, R., Bernard, D., et al., 2014. Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol. Ther., 22(1):206-218.

[22]Ni, Z., Fang, Q., Liu, D., et al., 2013. Effect of DC-CIK combined with chemotherapy on immune function, progression-free survival and quality of life of patients with breast cancer. Matern. Child Health Care China, 28(31):5134-5137 (in Chinese).

[23]Niu, Q., Wang, W., Li, Y., et al., 2011. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int. Immunopharmacol., 11(4):449-456.

[24]Olioso, P., Giancola, R., di Riti, M., et al., 2009. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol. Oncol., 27(3):130-139.

[25]Palucka, K., Banchereau, J., Mellman, I., 2010. Designing vaccines based on biology of human dendritic cell subsets. Immunity, 33(4):464-478.

[26]Pan, C.C., Huang, Z.L., Li, W., et al., 2010. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy. Chin. J. Cancer, 29(6):596-602.

[27]Ren, J., Di, L., Song, G., et al., 2013. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clin. Transl. Oncol., 15(10):780-788.

[28]Schmeel, L.C., Schmeel, F.C., Coch, C., et al., 2014. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J. Cancer Res. Clin. Oncol., 141(5):839-849.

[29]Schmidt-Wolf, I.G., Negrin, R.S., Kiem, H.P., et al., 1991. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med., 174(1):139-149.

[30]Schreiber, R.D., Old, L.J., Smyth, M.J., 2011. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science, 331(6024):1565-1570.

[31]Sheng, C., Bao, F., Xu, S., et al., 2011. Clinical research on chemotherapy combined with dendritic cell-cytokine induced killer cells for non-small cell lung cancer. J. Pract. Oncol., 26(5):503-506 (in Chinese).

[32]Shi, L., Zhou, Q., Wu, J., et al., 2012. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol. Immun., 61(12):2251-2259.

[33]Thanendrarajan, S., Nowak, M., Abken, H., et al., 2011. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk. Res., 35(9):1136-1142.

[34]Wang, D., Zhang, B., Gao, H., et al., 2014a. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer, 14(1):251.

[35]Wang, Z.X., Cao, J.X., Wang, M., et al., 2014b. Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis. Cytotherapy, 16(7):934-945.

[36]Wang, Z.X., Cao, J.X., Liu, Z.P., et al., 2014c. Combination of chemotherapy and immunotherapy for colon cancer in china: a meta-analysis. World J. Gastroenterol., 20(4):1095-1106.

[37]Yu, D., Han, Y., Zhao, Q., et al., 2014. CD3+ CD4+ and CD3+ CD8+ lymphocyte subgroups and their surface receptors NKG2D and NKG2A in patients with non-small cell lung cancer. Asian Pac. J. Cancer Prev., 15(6):2685-2688.

[38]Yuan, J., Peng, D., Li, J., 2011a. Clinical effects of administering dendritic cells and cytokine induced killer cell combined with chemo therapy in the treatment of advanced non-small cell lung cancer. J. Clin. Orthop., 16(12):1910-1911 (in Chinese).

[39]Yuan, J., Peng, D., Li, J., et al., 2011b. Clinical research of dendritic cells combined with cytokine induced killer cells therapy for advanced colorectal cancer. Chin. Gen. Pract., 12:4139-4141 (in Chinese).

[40]Yuan, Y., Niu, L., Mu, F., et al., 2013. Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer. Cryobiology, 67(2):235-240.

[41]Zhang, J., Geng, J., Han, Z., et al., 2011. Clinical effects of treatment of dendritic cells combined with cytokine induced killer cells therapy in patients with advanced colon carcinoma. Acta Acad. Med. Xuzhou, 31(7):457-459 (in Chinese).

[42]Zhong, R., Teng, J., Han, B., et al., 2011. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol. Immun., 60(10):1497-1502.

[43]Zhong, R., Han, B., Zhong, H., 2014. A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol., 35(2):987-994.

[44]Zhu, Y., Liu, J., Zhang, N., et al., 2011. Clinical effects of treatment with comprehensive multiple autologous immune cells in patients with colorectal carcinoma. Acta Acad. Med. Xuzhou, 9:631-636 (in Chinese).

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE